In Vitro Activity of a New Oral Glucan Synthase Inhibitor (MK-3118) Tested Against Aspergillus spp. by CLSI and EUCAST Broth Microdilution Methods.

JMI Laboratories, North Liberty, IA 52317, USA.
Antimicrobial Agents and Chemotherapy (Impact Factor: 4.48). 12/2012; 57(2). DOI: 10.1128/AAC.01588-12
Source: PubMed


MK-3118, a glucan synthase inhibitor derived from enfumafungin, and comparator agents were tested against 71 Aspergillus spp., including itraconazole-resistant strains (MIC, ≥4 μg/ml), using CLSI and EUCAST reference broth microdilution methods. CLSI MEC/MIC(90) values (μg/ml) for MK-3118, amphotericin B, and caspofungin, respectively, were: Aspergillus flavus species complex (SC), 0.12, 2, 0.03; A. fumigatus SC, 0.25, 2, 0.06; A. terreus SC, 0.12, 2, 0.06 and A. niger SC, 0.06, 1, 0.03. Essential agreement between CLSI and EUCAST (±2 log(2) dilution steps) was 94.3%. MK-3118 was determined to be a potent agent regardless of the in vitro method applied, with excellent activity against contemporary wild type and itraconazole-resistant strains of Aspergillus spp.

69 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Candida and Aspergillus species are important causes of opportunistic infection in an ever-growing number of vulnerable patients, and these infections are associated with high mortality. This has partly been attributed to the emerging resistance of pathogenic fungi to antifungal therapy, which potentially compromises the management of infected patients. Multi-azole resistance of Aspergillus fumigatus is a current health problem, as well as is the co-resistance of Candida glabrata to both azoles and echinocandins. In most cases, negative clinical consequences of reduced in vitro fungal susceptibility to azoles and/or echinocandins can be traced to acquisition of particular resistance mechanisms. While strategies using antifungal combinations or adjunctive agents that maximize the efficacy of existing antifungals may limit treatment failures, new therapeutic approaches, including antifungal agents with novel mechanisms of action, are urgent. In the meantime, more efforts should be devoted to close monitoring of antifungal resistance and its evolution in the clinical setting.
    Current Fungal Infection Reports 09/2013; 7(3). DOI:10.1007/s12281-013-0143-0
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Invasive fungal infections (IFIs) pose significant morbidity and are often life-threatening to many high-risk patients. Timely diagnosis and treatment of these infections with optimal therapy is imperative. Areas covered: Advances have been made in diagnostic biomarkers such as peptide nucleic acid fluorescent in situ hybridization, β-D-glucan and galactomannan, although more research is needed in this area to assist with both diagnosis and monitoring for improvement of IFI management. Novel antifungal agents (azole antifungals and echinocandins) are being investigated that have activity against Candida spp. and Aspergillus spp. Optimizing the pharmacodynamics (PD) of our current antifungal therapies through such strategies as continuous infusion of amphotericin B and dose escalation of echinocandins and liposomal formulations of amphotericin B have also been investigated with mixed results. Therapeutic drug monitoring (TDM) shows promise as evident from data with such agents as flucytosine, itraconazole, voriconazole and posaconazole. Expert opinion: The goal for the future of biomarkers in IFIs will be to have excellent sensitivity and specificity to ideally identify a particular fungus causing the infection or eliminate its existence to prevent unnecessary costs, resistance and antifungal usage. In addition, further developments of new antifungals are needed and judicious use of the current regimens needs to be optimized through antifungal PD properties and TDM.
    Expert Opinion on Pharmacotherapy 09/2013; 14(17). DOI:10.1517/14656566.2013.838217 · 3.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: MK-3118 is as an orally active new antifungal in the early stage of clinical development that inhibits the biosynthesis of β-(1,3)-glucan. We evaluated the in vitro activity of this compound against wild-type and echinocandin-resistant (ER) isolates containing mutations in the FKS gene(s) of Candida spp. and Aspergillus spp. MK-3118 demonstrated enhanced efficacy for most C. albicans and C. glabrata ER isolates relative to caspofungin, with decreased MICs and half-maximal inhibitory concentrations (IC50s).
    Antimicrobial Agents and Chemotherapy 02/2014; 58(2). DOI:10.1128/AAC.02145-13 · 4.48 Impact Factor
Show more


69 Reads
Available from